Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPH OTCMKTS:CNTTF NASDAQ:CYTK NASDAQ:GOSS NASDAQ:IMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$27.28+1.1%$26.02$20.39▼$53.96$1.26B0.8561,262 shs114,937 shsCNTTFCannTrust$0.00$4.35▼$11.97$1.01B4.52528,025 shs1.43 million shsCYTKCytokinetics$47.83+0.6%$40.30$29.31▼$59.39$5.73B0.621.89 million shs1.31 million shsGOSSGossamer Bio$3.07+2.5%$2.19$0.66▼$3.60$694.65M1.952.24 million shs1.37 million shsIMABI-Mab$3.63-1.6%$3.50$0.60▼$5.90$296.02M1.361.01 million shs783,530 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals-0.07%-5.00%-9.34%+6.47%-44.53%CNTTFCannTrust0.00%0.00%0.00%0.00%0.00%CYTKCytokinetics-4.42%-8.54%+22.11%+45.31%-15.31%GOSSGossamer Bio-6.56%-3.86%+50.25%+131.78%+232.70%IMABI-Mab-0.81%-11.72%-27.50%+58.37%+238.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$27.28+1.1%$26.02$20.39▼$53.96$1.26B0.8561,262 shs114,937 shsCNTTFCannTrust$0.00$4.35▼$11.97$1.01B4.52528,025 shs1.43 million shsCYTKCytokinetics$47.83+0.6%$40.30$29.31▼$59.39$5.73B0.621.89 million shs1.31 million shsGOSSGossamer Bio$3.07+2.5%$2.19$0.66▼$3.60$694.65M1.952.24 million shs1.37 million shsIMABI-Mab$3.63-1.6%$3.50$0.60▼$5.90$296.02M1.361.01 million shs783,530 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals-0.07%-5.00%-9.34%+6.47%-44.53%CNTTFCannTrust0.00%0.00%0.00%0.00%0.00%CYTKCytokinetics-4.42%-8.54%+22.11%+45.31%-15.31%GOSSGossamer Bio-6.56%-3.86%+50.25%+131.78%+232.70%IMABI-Mab-0.81%-11.72%-27.50%+58.37%+238.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 2.40Hold$31.6015.84% UpsideCNTTFCannTrust 0.00N/AN/AN/ACYTKCytokinetics 2.87Moderate Buy$75.3857.61% UpsideGOSSGossamer Bio 3.00Buy$8.50177.23% UpsideIMABI-Mab 3.00Buy$7.0092.84% UpsideCurrent Analyst Ratings BreakdownLatest CYTK, IMAB, CNTTF, GOSS, and AMPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025GOSSGossamer BioCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/10/2025IMABI-MabNew Street ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$7.009/9/2025IMABI-MabBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.009/8/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.009/3/2025CYTKCytokineticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$53.00 ➝ $71.009/3/2025CYTKCytokineticsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$60.00 ➝ $80.009/2/2025CYTKCytokineticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy9/2/2025CYTKCytokineticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$77.00 ➝ $84.009/2/2025CYTKCytokineticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$87.00 ➝ $96.009/2/2025CYTKCytokineticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$78.009/2/2025CYTKCytokineticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$72.00(Data available from 9/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$731.97M1.73$5.05 per share5.40$15.23 per share1.79CNTTFCannTrust$15.96M0.00N/AN/AN/ANaNCYTKCytokinetics$18.47M309.88N/AN/A($1.15) per share-41.59GOSSGossamer Bio$114.70M6.08N/AN/A$0.13 per share23.58IMABI-Mab$3.89M76.20N/AN/A$2.47 per share1.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$159.52M$2.6710.188.29N/A18.64%20.76%9.68%11/5/2025 (Estimated)CNTTFCannTrustN/A$0.07137.180.00N/AN/AN/AN/AN/ACYTKCytokinetics-$589.53M-$5.10N/AN/AN/A-707.17%N/A-45.52%11/5/2025 (Estimated)GOSSGossamer Bio-$56.53M-$0.62N/AN/AN/A-344.81%-1,774.72%-46.73%11/6/2025 (Estimated)IMABI-Mab-$22.23MN/A0.00N/AN/AN/A-19.65%-18.58%11/13/2025 (Estimated)Latest CYTK, IMAB, CNTTF, GOSS, and AMPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/20/2025Q2 2025IMABI-Mab-$0.10-$0.07+$0.03-$0.07N/AN/A8/7/2025Q2 2025CYTKCytokinetics-$1.34-$1.12+$0.22-$1.12$1.95 million$66.77 million8/5/2025Q2 2025GOSSGossamer Bio-$0.18-$0.17+$0.01-$0.17$4.12 million$11.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/ACNTTFCannTrustN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/AIMABI-MabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.803.292.21CNTTFCannTrustN/AN/AN/ACYTKCytokineticsN/A6.766.76GOSSGossamer Bio6.704.404.40IMABI-MabN/A22.8222.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%CNTTFCannTrust0.08%CYTKCytokineticsN/AGOSSGossamer Bio81.23%IMABI-Mab38.38%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals27.50%CNTTFCannTrustN/ACYTKCytokinetics2.70%GOSSGossamer Bio6.70%IMABI-Mab22.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals2,02846.49 million33.71 millionOptionableCNTTFCannTrustN/A105.61 millionN/ANot OptionableCYTKCytokinetics250119.66 million116.43 millionOptionableGOSSGossamer Bio180227.38 million212.15 millionOptionableIMABI-Mab38081.66 million63.61 millionOptionableCYTK, IMAB, CNTTF, GOSS, and AMPH HeadlinesRecent News About These CompaniesI-Mab (NASDAQ:IMAB) Earns Buy Rating from Analysts at BTIG ResearchSeptember 11, 2025 | marketbeat.comBTIG Research Begins Coverage on I-Mab (NASDAQ:IMAB)September 11, 2025 | americanbankingnews.comI-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By MarketSeptember 10, 2025 | seekingalpha.comNeedham & Company LLC Reaffirms Buy Rating for I-Mab (NASDAQ:IMAB)September 10, 2025 | marketbeat.comI-Mab (NASDAQ:IMAB) Given "Buy" Rating at Needham & Company LLCSeptember 10, 2025 | americanbankingnews.comBTIG Initiates Coverage of I-Mab - Depositary Receipt () (IMAB) with Buy RecommendationSeptember 9, 2025 | msn.comI-Mab initiated with a Buy at BTIGSeptember 9, 2025 | msn.comI-Mab Announces Leadership Changes and Accelerated Investment in GivastomigSeptember 9, 2025 | msn.comI-Mab announces accelerated investment in givastomig programSeptember 9, 2025 | msn.comI-Mab Announces Acceleration of Givastomig Investment and Leadership AppointmentsSeptember 9, 2025 | markets.businessinsider.comI-Mab to accelerate investment in givastomigSeptember 9, 2025 | msn.comI-Mab Sponsored ADR (NASDAQ:IMAB) Sees Large Increase in Short InterestSeptember 5, 2025 | marketbeat.comI-Mab Insiders Land Bargain With Gains Of US$5.0mAugust 31, 2025 | finance.yahoo.comAre You Looking for a Top Momentum Pick? Why I-Mab Sponsored ADR (IMAB) is a Great ChoiceAugust 28, 2025 | zacks.comStonepine Capital Management LLC Makes New $398,000 Investment in I-Mab Sponsored ADR $IMABAugust 26, 2025 | marketbeat.comHC Wainwright Comments on I-Mab's Q3 Earnings (NASDAQ:IMAB)August 26, 2025 | marketbeat.comI-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development CommitteeAugust 25, 2025 | globenewswire.comI-Mab (NASDAQ:IMAB) Upgraded by Wall Street Zen to "Buy" RatingAugust 25, 2025 | marketbeat.comNeedham & Company LLC Forecasts Strong Price Appreciation for I-Mab (NASDAQ:IMAB) StockAugust 23, 2025 | marketbeat.comI-Mab's (IMAB) Buy Rating Reiterated at HC WainwrightAugust 23, 2025 | marketbeat.comI-Mab (NASDAQ:IMAB) Announces Earnings Results, Beats Estimates By $0.03 EPSAugust 22, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYTK, IMAB, CNTTF, GOSS, and AMPH Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$27.28 +0.30 (+1.11%) As of 12:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.CannTrust OTCMKTS:CNTTFCannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.Cytokinetics NASDAQ:CYTK$47.83 +0.27 (+0.57%) As of 12:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Gossamer Bio NASDAQ:GOSS$3.07 +0.08 (+2.54%) As of 12:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.I-Mab NASDAQ:IMAB$3.63 -0.06 (-1.63%) As of 12:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why General Mills Is a Generational Opportunity for Income Investors Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? Is Netflix's Ad Deal With Amazon the Catalyst for a New Uptrend? DoorDash Buys Deliveroo: A Game Changer? The Side of Rate Cuts Nobody Is Telling You About Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
